Evidence map›Paper›PMID 40243337›Full record

ArticleJournal of virology2025

Protein-S-nitrosylation of human cytomegalovirus pp65 reduces its ability to undermine cGAS.

Justin B Cox, Masatoshi Nukui, Eain A Murphy

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Justin B CoxMicrobiology and Immunology Department, SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0003-3095-1512
Masatoshi NukuiMicrobiology and Immunology Department, SUNY Upstate Medical University, Syracuse, New York, USA.
Eain A MurphyMicrobiology and Immunology Department, SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0003-3449-5024

Funding

Alzheimer's Disease associated pathology induced by neurotropic viral infectionR01AG076007 · NIA · UPSTATE MEDICAL UNIVERSITY · PI MURPHY, EAIN A · 2021 to 2025
$3.0M
Antiviral responses of host mediated S-nitrosylation of viral proteins.R01AI155979 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI MURPHY, EAIN A · 2021 to 2025
$2.0M
NIAID NIH HHS R01 AI155979NIA NIH HHS R01 AG076007
6 · The paper itself

Abstract

Post-translational modifications (PTMs) are key regulators of various processes important for cell survival. These modifications are critical for dealing with stress conditions, such as those observed in disease states, and during infections with various pathogens. We previously reported that during infection of primary dermal fibroblasts, multiple human cytomegalovirus (HCMV)-encoded proteins were post-translationally modified by the addition of a nitric oxide group to cysteine residues, a modification called protein-S-nitrosylation. For example, tegument protein pp71 is nitrosylated, diminishing its ability to inhibit STING, a protein necessary for DNA virus immune response. Herein, we report that an additional HCMV tegument protein, pp65, responsible for the inhibition of cGAS is also modified by protein-S-nitrosylation on two cysteine residues. Utilizing site-directed mutagenesis to generate recombinant viruses that encode a pp65 that cannot be protein-S-nitrosylated, we evaluated the impact of this PTM on viral replication and how the virus impacts the cGAS/STING pathway. We report that the nitrosylation of pp65 negatively impacts its ability to block cGAS enzymatic functions. pp65 protein-S-nitrosylation mutants demonstrated a decrease in cGAS/STING-induced IRF3 and TBK1 phosphorylation. Additionally, we observed a reduction in IFN-β1 secretion in NuFF-1 cells expressing a nitrosylation-resistant pp65. We report that HCMV expressing a protein-S-nitrosylation-deficient pp65 is resistant to the activation of cGAS in the infection of primary dermal fibroblasts. Our work suggests that nitrosylation of viral proteins may serve as a broadly neutralizing mechanism in HCMV infection. IMPORTANCE: Post-translational modifications (PTM) are utilized by host cells to limit an invading pathogen's ability to establish a productive infection. A potent PTM, called protein-S-nitrosylation, has anti-bacterial and anti-viral properties. Increasing protein-S-nitrosylation with the addition of nitric oxide donor compounds reduced HCMV replication in fibroblasts and epithelial cells. We previously reported that protein-S-nitrosylation of HCMV pp71 limits its ability to inhibit STING. Herein, we report that the protein-S-nitrosylation of HCMV pp65 impacts its ability to limit cGAS activity, an additional protein important in regulating interferon response. Therapeutically, patients provided nitric oxide by inhalation reduced viral replication in coronavirus disease 2019, influenza, and even impacted bacterial growth within patients' lungs. It is thought that an increase in free nitric oxide increases the frequency of nitrosylated proteins. Understanding how protein-S-nitrosylation regulates a common DNA virus like HCMV will provide insights into the development of broadly neutralizing therapeutics in drug-resistant viral infections.

Indexed as

CytomegalovirusNucleotidyltransferasesPhosphoproteinsViral Matrix ProteinsCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseCytomegalovirus InfectionsFibroblastsHumansMembrane ProteinsNitric OxideProtein Processing, Post-TranslationalSTING ProteinVirus ReplicationcGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthasecytomegalovirus matrix protein 65kDaMembrane ProteinsNitric OxideNucleotidyltransferasesPhosphoproteinsSTING1 protein, humanSTING ProteinViral Matrix ProteinscGASHCMVherpesvirusespp65protein-S-nitrosylationPTMSTING

Identifiers

PMID40243337
PMCPMC12090748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.